Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies, for the joint development of an AI-based cancer pathology diagnostic support program.
Through this partnership, the companies aim to implement personalized healthcare solutions in society, specially for patients battling with cancer.
Under this deal, Chugai's scientific knowledge will be integrated with Biomy's platform for tumor microenvironment analysis, aiming to reduce the workload of pathologists and provide optimal treatment and diagnosis for individual patients.
Chugai's stock closed at $27.05, up 0.74 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.